Company Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Country | United States |
| IPO Date | May 7, 2015 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 197 |
| CEO | Joseph J. Ciaffoni |
Contact Details
Address: 100 Technology Center Drive Stoughton, Massachusetts 02072 United States | |
| Phone | 781-713-3699 |
| Website | collegiumpharma.com |
Stock Details
| Ticker Symbol | COLL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267565 |
| CUSIP Number | 19459J104 |
| ISIN Number | US19459J1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Thomas Heffernan B.S. Pharm, R.Ph. | Co-Founder and Independent Chairman |
| Joseph J. Ciaffoni | President, Chief Executive Officer and Director |
| Colleen Tupper | Executive Vice President and Chief Financial Officer |
| Shirley R. Kuhlmann | Executive Vice President, General Counsel, Chief Administrative Officer and Secretary |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer |
| Dr. Thomas B. Smith FAAFP, M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Christopher Shayne James M.D. | Vice President of Investor Relations |
| Bart J. Dunn | Executive Vice President of Strategy and Corporate Development |
| Scott Sudduth | Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | 8-K | Current Report |
| Apr 5, 2024 | ARS | Filing |
| Apr 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 29, 2024 | 144 | Filing |
| Feb 26, 2024 | 144 | Filing |
| Feb 22, 2024 | 10-K | Annual Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |